Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance (Q51161029)

31 March 2018

title

Pioglitazone for diabetes prevention in impaired glucose tolerance (English)

1 reference

31 March 2018

Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance (English)

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1010949

28 November 2024

0 references

1 reference

5

George A Bray

1 reference

31 March 2018

10

Abbas E Kitabchi

1 reference

31 March 2018

1

Ralph A DeFronzo

1 reference

31 March 2018

Devjit Tripathy

2

1 reference

31 March 2018

MaryAnn Banerji

4

1 reference

31 March 2018

Sunder Mudaliar

12

1 reference

31 March 2018

Ken Williams

14

1 reference

31 March 2018

Nicolas Musi

16

1 reference

31 March 2018

ACT NOW Study

18

1 reference

31 March 2018

Dawn C. Schwenke

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21428766

28 November 2024

Thomas A. Buchanan

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21428766

28 November 2024

Stephen C. Clement

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21428766

28 November 2024

Robert R. Henry

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21428766

28 November 2024

Howard N. Hodis

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21428766

28 November 2024

Wendy J. Mack

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21428766

28 November 2024

Robert E. Ratner

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21428766

28 November 2024

Frankie B. Stentz

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21428766

28 November 2024

Peter D. Reaven

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21428766

28 November 2024

language of work or name

English

0 references

publication date

1 March 2011

1 reference

31 March 2018

24 March 2011

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21428766

full work available at URL

28 November 2024

https://doi.org/10.1056/nejmoa1010949

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21428766

http://content.nejm.org/cgi/content/abstract/364/12/1104

28 November 2024

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21428766

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1010949

28 November 2024

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1010949

The New England Journal of Medicine

28 November 2024

published in

1 reference

31 March 2018

volume

364

1 reference

31 March 2018

issue

12

1 reference

31 March 2018

page(s)

1104-1115

1 reference

31 March 2018

Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002.

cites work

1

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1010949

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

28 November 2024

3

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1010949

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

28 November 2024

4

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1010949

10-year follow-up of intensive glucose control in type 2 diabetes

28 November 2024

5

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1010949

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

28 November 2024

6

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1010949

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

28 November 2024

7

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1010949

Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes

28 November 2024

8

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1010949

The DREAM trial – Authors' reply

28 November 2024

9

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1010949

Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program

28 November 2024

10

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1010949

Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women

28 November 2024

11

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1010949

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

28 November 2024

12

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1010949

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

28 November 2024

13

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1010949

Diagnosis and classification of diabetes mellitus

28 November 2024

14

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1010949

Actos Now for the prevention of diabetes (ACT NOW) study

28 November 2024

15

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1010949

The Role of Carotid Arterial Intima-Media Thickness in Predicting Clinical Coronary Events

28 November 2024

17

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1010949

Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial

28 November 2024

18

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1010949

Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp

28 November 2024

19

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1010949

Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose

28 November 2024

20

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1010949

Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study

28 November 2024

21

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1010949

Estimators and tests in the analysis of multiple nonindependent 2 x 2 tables with partially missing observations

28 November 2024

23

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1010949

beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis

28 November 2024

24

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1010949

Thiazolidinediones improve beta-cell function in type 2 diabetic patients

28 November 2024

25

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1010949

Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes

28 November 2024

26

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1010949

The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program

28 November 2024

27

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1010949

Association of A1C and fasting plasma glucose levels with diabetic retinopathy prevalence in the U.S. population: Implications for diabetes diagnostic thresholds

28 November 2024

28

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1010949

Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3.

28 November 2024

29

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1010949

Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study

28 November 2024

30

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1010949

The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study

28 November 2024

31

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1010949

10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study

28 November 2024

32

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1010949

Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study

28 November 2024

33

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1010949

Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone

28 November 2024

34

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1010949

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

28 November 2024

36

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1010949

Thematic review series: patient-oriented research. Imaging atherosclerosis: state of the art.

28 November 2024

37

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1010949

Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial

28 November 2024

38

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1010949

Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial

28 November 2024

39

1 reference

https://api.crossref.org/works/10.1056/NEJMOA1010949

28 November 2024

Identifiers

1 reference

31 March 2018

1 reference

31 March 2018